R&D | December 05, 2025
DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Angelini Ventures has already invested €125 million in 22 startups
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Patients can now get the starting 2.5 mg dose for $299 per month
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Roche says the move marks a step forward in its digital transformation strategy
Subscribe To Our Newsletter & Stay Updated
